Steven Grover retweetledi

Heterozygous FXII variant carriers protected against VTE with no risk for bleeding. In vivo validation further evaluated thrombin generation. This data further pushes FXII as a potential drug target that could prevent VTE in a safe and effective way!
doi.org/10.1038/s41467…
English























